Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 9/20 | 0.57 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.56 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | NADK | O95544 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788626 | 1.00 | AHCY (0.57) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL6445754 | 1.00 | AHCY (0.57) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL9777803 | 0.88 | AHCY (0.55) | AHCYPRMT5WDR77ADORA1NADK | |
| SCHEMBL24478703 | 0.84 | PRMT5 (0.73) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL22326785 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL21413837 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL800346 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL22326787 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL18520788 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL13173634 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 501 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024182811-A1 | COMPOSITIONS AND METHODS FOR TREATING UTERINE LEIOMYOMAS | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-09-06 | — | — | WO | claimed |
| US-9320753-B2 | Organ arrest, protection and preservation | HIBERNATION THERAPEUTICS, A KF LLC (US) | 2016-04-26 | — | — | US | claimed |
| US-20130224110-A1 | USE OF ADENOSINE RECEPTOR SIGNALING TO MODULATE PERMEABILITY OF BLOOD-BRAIN BARRIER | CORNELL UNIVERSITY (US) | 2013-08-29 | — | — | US | claimed |
| EP-2616538-A1 | USE OF ADENOSINE RECEPTOR SIGNALING TO MODULATE PERMEABILITY OF BLOOD-BRAIN BARRIER | Cornell University (US) | 2013-07-24 | — | — | EP | claimed |
| US-20130184231-A1 | ORGAN ARREST, PROTECTION AND PRESERVATION | HIBERNATION THERAPEUTICS LIMITED (AU) | 2013-07-18 | — | — | US | claimed |
| WO-2012037457-A1 | USE OF ADENOSINE RECEPTOR SIGNALING TO MODULATE PERMEABILITY OF BLOOD-BRAIN BARRIER | CORNELL UNIVERSITY (US) | 2012-03-22 | — | — | WO | claimed |
| US-20100298254-A1 | ORGAN ARREST, PROTECTION AND PRESERVATION | HIBERNATION THERAPEUTICS LIMITED (AU) | 2010-11-25 | — | — | US | claimed |
| US-20070270372-A1 | arresting heart of subject in need of heart surgery by exposing heart to effective amounts of a compound chosen from a potassium channel opener, a potassium channel agonist, an adenosine receptor agonist, and a local anaesthetic under conditions sufficient for heart to be arrested | HIBERNATION THERAPEUTICS LIMITED (AU) | 2007-11-22 | — | — | US | claimed |
| EP-1790223-A1 | Organ arrest, protection and preservation | Hibernation Therapeutics Limited (AU) | 2007-05-30 | — | — | EP | claimed |
| US-7223413-B2 | Composition of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; heart can be better protected during arrest and recovery by using the potassium channel opener adenosine and the local anaesthetic lignocaine | HIBERNATION THERAPEUTICS LIMITED (AU) | 2007-05-29 | — | — | US | claimed |
| EP-1168912-A4 | ORGAN ARREST, PROTECTION AND PRESERVATION | UNIV JAMES COOK (AU) | 2002-07-31 | — | — | EP | claimed |
| US-20020058669-A1 | PROCESS FOR THE TREATMENT OF ORGANOPHOSPHATE POISONING | NEDERLANDSE ORGANISATIE VOR TOEGEPASTNATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2002-05-16 | — | — | US | claimed |
| EP-1168912-A1 | ORGAN ARREST, PROTECTION AND PRESERVATION | James Cook University (AU) | 2002-01-09 | — | — | EP | claimed |
| EP-1087776-A1 | A PROCESS FOR THE TREATMENT OF ORGANOPHOSPHATE POISONING | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2001-04-04 | — | — | EP | claimed |
| WO-2000056145-A1 | ORGAN ARREST, PROTECTION AND PRESERVATION | JAMES COOK UNIVERSITY (AU) | 2000-09-28 | — | — | WO | claimed |
| US-6093417-A | Composition to treat ear disorders | ADVANCED MEDICAL INSTRUMENTS (US) | 2000-07-25 | — | — | US | claimed |
| WO-1999065501-A1 | A PROCESS FOR THE TREATMENT OF ORGANOPHOSPHATE POISONING | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 1999-12-23 | — | — | WO | claimed |
| EP-0689405-A4 | METHODS FOR PROTECTING TISSUES AND ORGANS FROM ISCHEMIC DAMAGE | GENSIA INC (US) | 1996-09-11 | — | — | EP | claimed |
| EP-0689405-A1 | METHODS FOR PROTECTING TISSUES AND ORGANS FROM ISCHEMIC DAMAGE | GENSIA, INC. (US) | 1996-01-03 | — | — | EP | claimed |
| WO-1994021195-A1 | METHODS FOR PROTECTING TISSUES AND ORGANS FROM ISCHEMIC DAMAGE | GENSIA, INC. (US) | 1994-09-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058669-A1 | PROCESS FOR THE TREATMENT OF ORGANOPHOSPHATE POISONING | ADORA3, ADORA1, ADORA2A | AHCY 369/4885PRMT5 2315/4885WDR77 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.